Equity Profile

TWST

TWIST BIOSCIENCE COR

Health CareBiotechnology$4.3B

Aug3Mon

Pre-Earnings Brief

UpcomingQ3-2026Pre-Market9:00 AM EDT

Company Snapshot

Twist Bioscience Corporation (TWST) operates in the biotechnology sector, focusing on DNA synthesis and gene editing technologies. Their innovative approach is significant for various applications, including pharmaceuticals, agriculture, and synthetic biology, making them a key player in the health care industry.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, and investors will be keen to see if the company can reduce its losses this quarter.

N/A

Revenue Growth

While specific revenue estimates are not available, any indication of growth or new contracts can signal demand for their products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2-2026, Twist reported an EPS of -$0.71, missing expectations by 31.48%. Following this disappointing result, the stock fell by nearly 7% the next day.

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to advancing their product pipeline.
Plans to enhance customer engagement and expand market reach.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of missing EPS estimates. Investors are cautious but hopeful for signs of recovery.

Bull Case

If Twist can demonstrate significant progress in reducing losses and show promising developments in their product pipeline, it could lead to a positive market reaction.

Bear Case

On the other hand, continued losses and lack of revenue growth could further undermine investor confidence, leading to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is management taking to reduce the EPS loss this quarter?

Given the recent trend of missing EPS estimates, any concrete plans for improvement will be closely scrutinized by investors.

Can Twist provide updates on their product pipeline and any new contracts?

New developments or contracts could indicate future revenue growth, which is crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Twist's potential for a turnaround due to their innovative product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

Despite recent losses, the company's technology remains at the forefront of biotechnology, with applications that could drive future demand.

The significant implied move in options suggests traders expect a major shift, which could indicate hidden optimism not reflected in current stock prices.

Key Risk

If the company can announce new contracts or partnerships, it could invalidate the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Twist can turn around its financial performance and capitalize on its innovative technologies.

Bull Confirmed If

A reduction in EPS loss to below -$0.50 would signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.71 would confirm ongoing struggles and potentially lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±39.26%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

19,268 sh

2 insiders

Net

$1.2M

Net selling

Most Active Insiders· 6 open-market trades

Chief Executive OfficerLeproust Emily M.
$630,957.35

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations and raises guidance, history suggests a potential stock increase of around +0.91%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity from management.

Miss

If the company misses again, history suggests a decline of about -6.11%, which could further shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any new partnerships.
2Management's strategy for reducing EPS losses.
3Details on R&D spending and its impact on future growth.
4Any commentary on customer engagement and market expansion efforts.
5Insights into competitive positioning within the biotechnology sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul31

SONYBMO

Sony Group Corporation

PreviewView

Jul31

ENBBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a critical measure of profitability, and investors will be keen to see if the company can reduce its losses this quarter.

N/A

Revenue Growth

While specific revenue estimates are not available, any indication of growth or new contracts can signal demand for their products.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

TWST Q3-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+5.33%

Avg Stock Reaction

-3.48%

Last Quarter Recap

In Q2-2026, Twist reported an EPS of -$0.71, missing expectations by 31.48%. Following this disappointing result, the stock fell by nearly 7% the next day.

Management Promises & Guidance

Focus on improving operational efficiency.
Commitment to advancing their product pipeline.
Plans to enhance customer engagement and expand market reach.

Expectations

Wall Street Expectations

Overall, expectations are mixed as the company has a history of missing EPS estimates. Investors are cautious but hopeful for signs of recovery.

Bull Case

If Twist can demonstrate significant progress in reducing losses and show promising developments in their product pipeline, it could lead to a positive market reaction.

Bear Case

On the other hand, continued losses and lack of revenue growth could further undermine investor confidence, leading to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific steps is management taking to reduce the EPS loss this quarter?

Given the recent trend of missing EPS estimates, any concrete plans for improvement will be closely scrutinized by investors.

Can Twist provide updates on their product pipeline and any new contracts?

New developments or contracts could indicate future revenue growth, which is crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Twist's potential for a turnaround due to their innovative product pipeline, which could lead to unexpected revenue growth.

Supporting Evidence

Despite recent losses, the company's technology remains at the forefront of biotechnology, with applications that could drive future demand.

The significant implied move in options suggests traders expect a major shift, which could indicate hidden optimism not reflected in current stock prices.

Key Risk

If the company can announce new contracts or partnerships, it could invalidate the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is debating whether Twist can turn around its financial performance and capitalize on its innovative technologies.

Bull Confirmed If

A reduction in EPS loss to below -$0.50 would signal improved operational efficiency.

Bear Confirmed If

An EPS loss greater than -$0.71 would confirm ongoing struggles and potentially lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±39.26%

Historical Avg

±10.2%

Pricing rich

The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings announcement.

Options are pricing ±39.3% while TWST has averaged ±10.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

71.2%

Calls (17K)P/C Ratio: 0.13Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.2M

19,268 sh

2 insiders

Net

$1.2M

Net selling

Most Active Insiders· 6 open-market trades

Chief Executive OfficerLeproust Emily M.
$630,957.35

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Twist beats expectations and raises guidance, history suggests a potential stock increase of around +0.91%, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await more clarity from management.

Miss

If the company misses again, history suggests a decline of about -6.11%, which could further shake investor confidence.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any new partnerships.
2Management's strategy for reducing EPS losses.
3Details on R&D spending and its impact on future growth.
4Any commentary on customer engagement and market expansion efforts.
5Insights into competitive positioning within the biotechnology sector.